Cytotoxic T-lymphocyte antigen 4-immunoglobulin (CTLA4Ig) is soluble version of the T-cell transmembrane glycoprotein receptor CTLA-4; it is a recombinant chimeric fusion protein consisting of the extracellular domain of human CTLA-4 and the Fc region (hinge, CH2 and CH3) of human IgG.1) CTLA4Ig has demonstrated immunosuppressive activity and the ability to induce immune tolerance in several in vivo animal models.2) It is produced as a disulfidelinked dimer. Hence it is a ca. 100 kDa dimer under nonreducing conditions, and a ca. 50 kDa monomer under reducing conditions.3) It has two potential N-glycosylation sites (Asn 78, Asn 111) in the CTLA-4 portion 4) and one (Asn 297) in the Fc portion. 5) Recently recombinant CTLA4Ig produced in Chinese hamster ovary (CHO) cells was approved by the US Food and Drug Administration (FDA).6) CHO cell-derived recombinant human CTLA4Ig (crhCTLA4Ig) has a2,3-linked sialic acids, and the terminal sialic acids are important for its in vivo stability. 7) Recombinant CTLA4Ig has also been produced in rice cells. 6,8) Production in transgenic plants has low investment and operating costs, 9,10) and downstream processing has obvious economic advantages over traditional fermentation methods because recombinant proteins can be produced in plants at 2-10% of the cost of microbial fermentation systems and at 0.1% of the cost of mammalian cell culture. 11,12) N-Linked glycans in plants have a core substituted by two N-acetylglucosamine (GlcNAc) residues, as observed in mammals. However, plant N-glycans lack galactose and terminal sialic acids, and have plant-specific a1,3-fucose and b1,6-xylose residues.13) The lack of terminal sialic acids in plant cellderived glycoproteins has limited their use as therapeutic agents.13) However, recent reports of Shah et al. 14) and Takashima et al. 15) revealed a possible genetic and enzymatic basis for sialylation in plants and thus the potential for terminal sialylation of glycoproteins. However, there has been no report concerning the terminal sialylation of plant cell-derived glycoproteins. There have been few attempts to produce CTLA4Ig in prokaryotes, and there is therefore no information about the in vivo stability and molecular weight of nonglycosylated CTLA4Ig.In this study, we analyzed the terminal sialylation of rice cell-derived recombinant human CTLA4Ig (rrhCTLA4Ig). After chemical deglycosylation, we determined the molecular weight of non-glycosylated CTLA4Ig and the glycosylation ratios of rrhCTLA4Ig and crhCTLA4Ig. We also evaluated the pharmacokinetics of rrhCTLA4Ig and crhCTLA4Ig as well as of their deglycosylated forms after intravenous (i.v.) and subcutaneous (s.c.) administration to rats.
MATERIALS AND METHODSProteins rrhCTLA4Ig was expressed and purified as described in Lee et al. 6) crhCTLA4Ig was used as a control in the chemical deglycosylation and pharmacokinetic experiments. In the previous report of Jung et al. 8) and Lee et al.,6) it is known that rrhCTLA4Ig and crhCTLA4Ig have similar in vitro immunosuppressive activit...